Lilly Oncology



From 2012 to 2021, Rose Li and Associates (RLA) partnered with Lilly Oncology to advance evidence-based solutions in the fight against cancer. In 2012, the Patient Access to Cancer care Excellence (PACE) Global Council convened to identify potential barriers to innovation in oncology research and develop strategies to remove obstacles to improved cancer care. The need for consensus-building among stakeholders and opinion leaders surrounding the significance of continuous innovation in oncology treatment emerged. In 2015, RLA developed and launched the Continuous Innovation Indicators™ (CII), an online analytic platform that measures progress in 12 solid tumor cancers. Its goal was to encourage public policies and health care decisions that speed the development of new medicines, increase responsiveness to the unmet needs of patients, and improve patient access to the most effective cancer treatments.

How We Helped

Initially, RLA’s role consisted of conducting an analysis of the public policy environment and identifying barriers to rapid research and development in oncology. Development of the CII soon followed—the first, evidence-based, customizable online tool to review progress against cancer over time. The CII provides an interactive platform for conducting a variety of analyses across 12 types of cancer. RLA annually updates the CII (through 2020) with the latest published clinical data. Watch a White Board Video or Download Brochure of the CII. From this collaboration, RLA has also produced noteworthy publications. For example, one paper measured the value of surrogate endpoints in oncology dynamic assessments (2017), and another investigated the utility of real-world evidence in personalized medicine using homomorphic encryption. This proof-of-concept paper was selected by the International Medical Informatics Association (IMIA) as one of the three best papers in clinical research informatics published in 2019.

Looking Forward

RLA continues to explore opportunities to build on its past efforts in evidence-based oncology research that benefits patients and fosters innovative industry collaboration. We continue to harness the CII’s unique utility of published clinical data to identify long-term trends, impactful advances, and unmet patient needs, thus informing audiences of the novel advancements in oncology research. This experience has positioned RLA as a leader in oncology health policy analysis with the ability to assess international oncology frameworks and leverage the CII’s potential into novel areas such as program evaluation.

Work Products and Links

Access the CII interactive tool!

The Cancer Policy Environment: Barriers to Faster Oncology Innovation, and Strategies for Moving Forward (November 2012)

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments (eCancerMedicalScience, 2015)

Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators (Future Oncology, 2017)

The PACE continuous innovation Indicators: A flexible tool to evaluate progress in cancer treatments (Journal of Clinical Oncology, 2017)

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII) (Drugs in Context, 2017)

Proof-of-concept study: Homomorphically encrypted data can support real-time learning in personalized cancer medicine (BMC Medical Informatics and Decision Making, 2019)